Q1 FY27 Results: Revenue up 30%, PAT more than doubles YoY

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionEmphasis Of MatterResults View source PDF

VENUSREM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+0.3%1-day move

₹1682.20

prior close

₹1621.10

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+7.5+9.7+9.7+9.7+0.3-1.9-2.1-6.5-8.8—————

Up moveDown movePending

AI summary

Venus Remedies posted strong Q1 FY27 results. Standalone revenue rose to Rs 178.80 Cr from Rs 137.13 Cr, about 30 percent YoY growth. Net profit surged to Rs 25.53 Cr from Rs 11.70 Cr, more than doubling. EBITDA climbed to Rs 39.11 Cr. Consolidated PAT at Rs 22.97 Cr versus Rs 9.60 Cr. Board also approved revisions to MOA and AOA. Auditor flagged emphasis of matter on Rs 28.60 Cr outstanding share application money in German subsidiary Venus Pharma GmbH undergoing restructuring.

Likely market impact

Strong Q1 with revenue and PAT both showing robust YoY growth. Watch for recovery of German subsidiary exposure and AGM outcome on MOA changes.